The ALPACA study: (In)Appropriate LAMA prescribing in asthma: A cohort analysis

E.J. Baan a,*, 1, C.E. Hoeve a,1, M. De Ridder a, L. Demoen b, L. Lahousse b, G.G. Brusselle c,d, K.M. C. Verhamme a,b

a Department of Medical Informatics, Erasmus Medical Centre, Rotterdam, Netherlands
b Department of Bioanalysis, Ghent University, Ghent, Belgium
c Department of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium
d Department of Epidemiology and Respiratory Medicine, Erasmus Medical Centre, Rotterdam, Netherlands

A R T I C L E   I N F O

Keywords:
Asthma
Therapy
Epidemiology
Safety

A B S T R A C T

Introduction: Since long-acting muscarinic antagonists (LAMA) are only indicated as add-on therapy in subjects with moderate-to-severe asthma, there are concerns whether LAMA monotherapy is associated with worse asthma control.
Aim: To study the prevalence of LAMA monotherapy and its potential association with severe asthma exacerbations (SAE) in patients with asthma.
Methods: A cohort study (2007–2017) in the IPCI primary care database, in asthma patients aged 6–50, using LAMA during follow-up. Respiratory prescriptions were retrieved from the electronic medical records based on ATC code. Asthma treatment periods were created and categorized as LAMA mono, dual (LAMA + ICS), or triple therapy (LAMA + ICS + LABA). Relative rates (RR) of SAE, adjusting for patient characteristics, were estimated to compare treatments.
Results: From a total of 66,508 asthma patients, 1236 (1.9%) LAMA users were identified. Median age was 41 years, 65.9% were females. LAMA users were responsible for 3596 LAMA treatment periods of which 1390 (38.7%) were LAMA monotherapy, 553 (15.4%) dual therapy and 1653 (46.0%) triple therapy. The RR of SAE during LAMA monotherapy compared to dual therapy was 1.5 (95% CI 0.6–3.8). In patients alternating between mono and dual therapy (but never triple therapy), the RR for LAMA monotherapy increased to 5.7 (95% CI 1.4–23.6).
Conclusions: This observational study shows that when LAMA is prescribed, it is often prescribed without concomitant ICS (LAMA monotherapy). LAMA monotherapy was associated with an increased risk of exacerbations when not used concurrently with ICS. This emphasizes the importance that LAMA should never be prescribed without concomitant ICS use in patients with asthma.

1. Introduction

Inhaled corticosteroids (ICS) are the cornerstone of asthma treatment. However, in some patients additional medication is required to control symptoms, prevent exacerbations and improve the quality of life. The preferred add-on medication in asthmatic patients is a long-acting beta2 agonist (LABA). Other options are leukotriene receptor antagonists (LTRA) or long-acting muscarinic antagonists (LAMA) [1]. LAMA is most commonly used in patients with COPD, however since 2014 it is also registered for treatment in patients with severe asthma aged 6 years or older [2]. Trials have shown that LAMA - as an add-on to ICS in uncontrolled asthma - reduces the risk of an asthma exacerbation and improves lung function, but no significant effect on asthma control questionnaires or quality of life has been observed [3,4]. Since most evidence on the use of LAMA in asthmatic patients is based on tiotropium, tiotropium is currently the only LAMA indicated for use in asthma. The Global Initiative for Asthma (GINA) recommends the use of tiotropium in step 4 and 5 of asthma treatment, as an add-on treatment

* Corresponding author.
E-mail address: e.baan@erasmusmc.nl (E.J. Baan).
1 Both authors contributed equally to the work and manuscript.

https://doi.org/10.1016/j.pupt.2021.102074
Received 31 March 2021; Received in revised form 1 June 2021; Accepted 18 August 2021
Available online 20 September 2021
1094-5539/© 2021 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
only, when asthma control cannot be achieved with a combination of ICS and LABA [1].

Treatment adherence is often suboptimal in asthmatic patients [5]. One study using a US claims database reported that amongst asthma patients using tiotropium, in almost one out of five patients this use consisted of tiotropium monotherapy, i.e. without a concurrent ICS prescription [6]. This is alarming, as studies have shown that LABA, also a controller therapy, if used in monotherapy increases the risk of asthma exacerbations and even asthma-related death [7,8]. The effect of LAMA monotherapy on asthma control is not yet known. The aim of this study is to examine the use of LAMA monotherapy in asthmatic patients and to investigate whether LAMA monotherapy increases the risk of severe asthma exacerbations using data from a primary care electronic healthcare database.

2. Methods

2.1. Data source and study design

A retrospective cohort study was conducted using data from the Integrated Primary Care Information (IPCI) database. IPCI is a primary care database containing the complete electronic patient records from approximately 2.5 million patients in the Netherlands [9]. The study period was from January 1, 2007 to December 31, 2017. Patients were included if they were 6–50 years old during the study period, with physician diagnosed asthma (ICPC = R96) in combination with at least two asthma drug prescriptions (Anatomical Therapeutic Chemical Classification System (ATC) code R03) within one year of any available asthma diagnosis code. In addition, patients had at least one year of database history, and at least one LAMA prescription during the study period. Patients with a COPD diagnosis code (ICPC = R95) were excluded. The follow-up started on the date of database entry, asthma diagnosis, reaching the age of 6 years or study start, whichever came last. The follow-up ended at the age of 50 years, death, lost-to-follow up, or end of study period, whichever came first.

2.2. Exposure

From the individual prescriptions, treatment periods were created from consecutive prescriptions within 30 days. At the start of each treatment period, a washout-period of 30 days was applied (see online supplements) implying that follow-up only started after 30 days treatment. This washout was applied to reduce the effect of previous treatment periods on subsequent treatment periods. Since the washout reduced the duration of the follow-up period sensitivity analyses without wash-out periods were also conducted.

For the analysis the treatment periods were categorized into three types of LAMA-therapy use, and patients were categorized into four types of LAMA-users based on all their treatment periods during follow-up.

1. Treatment period types

LAMA-therapy treatment periods were classified in 3 categories: 1) monotherapy (LAMA): a treatment period of a LAMA exposure with no simultaneous ICS exposure; 2) dual therapy (LAMA + ICS): a treatment period of LAMA exposure overlapping with a treatment period of ICS, but with no simultaneous LABA exposure; 3) triple therapy (LAMA + ICS + LABA): a treatment period of LAMA prescription overlapping with ICS and LABA exposure (Fig. 1).

2. Patient types

Patients were categorized into four patient types based on their respective treatment periods during complete follow-up: 1) only LAMA mono use: patients only using LAMA monotherapy; 2) only LAMA dual use: patients only dual therapy (LAMA + ICS); 3) mixed: patients using both mono and dual therapy; 4) triple: patients using at least once triple therapy.

2.3. Outcome measures

Our primary outcome was the occurrence of severe asthma exacerbations (SAE). SAE were defined as a burst of systemic corticosteroids for at least 5 days and maximum 30 days (ATC-code starting with H02AB), an emergency department visit or a hospitalization, all for reason of asthma [10,11]. A cut-off of a minimum of 5 days of systemic corticosteroids was chosen as this is in alignment with the Dutch guidelines [12]. All potential exacerbations were automatically selected from the electronic medical records and validated by two researchers (EB and CH). Initially we also aimed to study the effect on mortality however as the number of asthma patients who died in our study population was (fortunately) too small (n = 0), this analysis could not be conducted.

2.4. Covariates

Patient characteristics (age, sex, SAE in the previous year, smoking and comorbidities) were determined at the start of each treatment period. The number of SAEs were determined in the year before each treatment period and used as a continuous variable to be able to adjust for the history of asthma exacerbations. Comorbidities were identified based on an ICPC specific search. Details of these ICPC codes are described in the online supplement.

2.5. Analysis

We described the characteristics of patients by patient type (mono, dual, mixed, or triple) and calculated p-values for the differences in characteristics between the groups (chi-square test or fisher exact test for dichotomous and categorical variables, and Kruskal-Wallis or
ANOVA for continuous variables as applicable). Crude exacerbation rates were calculated as the number of exacerbations divided by the total follow-up time. A Poisson regression analysis was performed to study the relative risk of asthma exacerbations for LAMA monotherapy exposure periods using LAMA + ICS dual therapy as reference category, adjusting for patient characteristics. Furthermore, subgroup analyses were performed based on patient type as these patient types are likely to reflect the severity of asthma. For these analyses the AER package for GEE modeling was used to allow for repeated measures as one patient could be exposed to multiple treatment periods during follow-up. In case the correlation matrix coefficient was low (indicating that there is a low correlation between repeated measures of patients), a GLM Poisson model was used instead. All analyses were done with R version 3.6.1 using packages: AdhereR, AER, dplyr, gee, glm, lme4, MASS, nlme, pglm, reshape, reshape2, tableone, tidyr). The risk window for exacerbations was defined as the duration of the treatment episodes (Fig. 2) after the wash-out period. A sensitivity analysis was done to evaluate outcomes without washout period.

3. Results

In total, there were 66,508 asthma patients aged between 6 and 50 years in the period from 2007 to 2017, of which 1236 (1.9%) patients used LAMA. The median age was 43 years and 65.9% were females. A total of 3596 LAMA treatment periods were generated, of which 1390 (38.7%) were LAMA mono therapy with a median duration of 38 days, 553 (15.4%) LAMA and ICS dual therapy with a median of 58 days and 1653 (46.0%) triple therapy with a median of 60 days (Table 1). LAMA prescription consisted for 93% of tiotropium. The majority of LAMA patients used at least once triple therapy (n = 852, 69.0%), 74 (6.0%) patients used both monotherapy and dual therapy, 89 (7.2%) patients used only LAMA + ICS dual therapy, and 221 (17.9%) patients only used monotherapy (Table 1).

3.1. Patient characteristics by type of LAMA use

Patient characteristics according to type of LAMA use are described in Table 2. The proportion of females differed significantly between the different patient user types (p = 0.045) ranging from 64.4% in the triple therapy users to 76.4% in the LAMA and ICS dual users. The median age of patients was 43 years, with no significant difference across the groups.

The most common comorbidities were allergic rhinitis (range 24.3–31.2%), eczema (range 10.8–20.2%), and depression (range 9.0–18.1%). Patients exposed to triple therapy (ICS + LAMA + LABA) had slightly more comorbidities than patients on mono, dual or mixed therapies. However, for none of the comorbidities this difference was significant. Smoking status was significantly different across the groups, with more current (46.5%) and past (13.8%) smokers in patients who only used LAMA in monotherapy compared to the other three exposure types. Patients who were exposed to triple therapy more often had a SAE in the year before treatment with 30% having at least one severe exacerbation in the year prior. In contrast, the proportion of patients with a history of SAE was much lower in patients who only used LAMA in monotherapy where 14% had at least one SAE in the year before LAMA treatment.

3.2. Differences in risk of exacerbations

A total of 201 severe asthma exacerbations occurred during LAMA treatment periods (either in monotherapy or in combination with ICS or ICS + LABA). The absolute risk was highest during treatment periods consisting of triple therapy (0.56/1000 treatment days; 95% CI 0.48–0.65/1000 treatment days), followed by monotherapy (0.21/1000 treatment days; 95% CI 0.15–0.31/1000 treatment days) and LAMA and ICS dual therapy (0.15/1000 treatment days; 95% CI 0.08–0.27/1000 treatment days). The relative risk (RR) of SAE, after adjustment for confounders such as smoking, during LAMA monotherapy compared to dual therapy was 1.50 (p = 0.387) (Table 3). The risk of SAE was significantly higher during triple therapy than dual therapy with an RR of 3.80 (p < 0.001). After adjusting for potential confounders such as prior exacerbation rate, the RR remained significant at 2.75 (p = 0.025) (Table 3).

Next the analysis was repeated but now in a more homogenous group of patients with both exposure periods of LAMA monotherapy and exposure periods of dual therapy. None of these patients had been prescribed triple therapy during the study period, and all had at least once a concomitant prescription of ICS + LAMA. Compared to periods of dual therapy, during monotherapy patients had a relative risk of SAE of 2.1 (p = 0.045) and after adjusting for potential confounders 5.7 (p = 0.016) (Table 3).

We performed a sensitivity analysis in which treatment periods were determined without washout period. Results were comparable to those when considering a washout-period. The risk of exacerbations was higher during triple and monotherapy periods compared to dual therapy.

| Table 1 |
| Number of treatment periods per patient type. All categories are mutually exclusive. Total duration of treatment periods were: LAMA monotherapy: 127,660 patient days; Dual therapy: 74,728 patient days; Triple therapy: 312,259 patient days. |

| Patient type | Treatment period | Mono n | Only Dual (LAMA and ICS) n | Mixed n | Triple n |
|--------------|------------------|--------|---------------------------|---------|----------|
|              | (n = 340)        | 0      | 165                        | 885     |
|              | (n = 553)        | 0      | 116                        | 164     | 273      |
|              | (n = 1653)       | 0      | 0                          | 0       | 1653     |

![Fig. 2. Risk window. The risk window is defined as the duration of treatment excluding the washout period. Blue arrows represent exacerbations within the risk window and are counted in the exacerbation rate. Red arrows represent exacerbations outside the risk window and are thus excluded. The exacerbation rate during the treatment period is 3/75 patient days = 0.04.](image-url)
periods, though this was only statistically significant for triple therapy. In mixed patients only, the risk of exacerbations was again significantly higher during monotherapy compared to dual therapy (RR 4.9, p-value 0.015). For details see online supplements.

To investigate whether the increased risk of exacerbations was driven by LABA use, we also repeated the analyses for LAMA monotherapy prescriptions without concurrent LABA prescriptions, the results were not statistically significant. Details on these analyses can be found in the online supplements.

A stratified analysis on history of severe asthma exacerbation showed an increased risk of SAE during LAMA monotherapy for mixed patients without a SAE in the year prior (RR: 2.68, CI 95% 1.49–4.82), and for all patients with a SAE in the year prior (RR = 16.36, CI 95% 1.68–159.18). Details on these analyses can be found in the online supplements.

### Table 2

Patient characteristics (determined at the start of first treatment period of interest) of all patients included in the study cohort stratified by patient type. Patients are categorized into four types of LAMA exposure.

| Patient type | Only mono | Only dual | Mixed | Triple | p-value |
|--------------|-----------|----------|-------|--------|---------|
| Number of patients | 221       | 89       | 74    | 852    |         |
| Female gender (%) | 158 (71.5) | 68 (76.4) | 49 (66.2) | 549 (64.4) | 0.045   |
| Age (median) | 44.3 (38.9–47.2) | 43.4 (34.5–47.6) | 42.9 (34.3–46.2) | 42.7 (35.6–46.4) | 0.261   |
| GERD (%) | 18 (8.1) | 8 (9.0) | 2 (2.7) | 95 (11.2) | 0.086   |
| Obesity (%) | 20 (9.0) | 7 (7.9) | 3 (4.1) | 94 (11.0) | 0.206   |
| Diabetic Mellitus (%) | 7 (3.2) | 3 (3.4) | 2 (2.7) | 59 (6.9) | 0.069   |
| Allergic rhinitis (%) | 64 (29.0) | 27 (30.3) | 18 (24.3) | 266 (31.2) | 0.619   |
| Chronic rhinosinusitis (%) | 14 (6.3) | 6 (6.7) | 3 (4.1) | 45 (5.3) | 0.817   |
| Nasal polyposis (%) | 1 (0.5) | 0 (0.0) | 0 (0.0) | 7 (0.8) | 0.661   |
| Eczema (%) | 29 (13.1) | 18 (20.2) | 8 (10.8) | 125 (14.7) | 0.320   |
| Allergic conjunctivitis (%) | 6 (2.7) | 2 (2.2) | 0 (0.0) | 29 (3.4) | 0.391   |
| Depression (%) | 40 (18.1) | 8 (9.0) | 9 (12.2) | 127 (14.9) | 0.197   |
| Number of patients with ≥1 lower respiratory tract infections in previous year | 36 (16.3) | 10 (11.2) | 16 (21.6) | 135 (15.8) | 0.351   |
| Severe asthma exacerbations in previous year (%) | 190 (86.0) | 69 (77.5) | 62 (83.8) | 596 (70.0) | <0.001 |
| Smoking (%) | 65 (40.6) | 36 (60.0) | 35 (57.4) | 355 (55.1) |         |
| Past | 74 (46.5) | 17 (28.3) | 19 (31.1) | 215 (33.4) |         |
| Current | 22 (13.8) | 7 (11.7) | 7 (11.5) | 74 (11.5) |         |
| Never | 0 (0.0) | 0 (0.0) | 0 (0.0) | 7 (0.8) | 0.661   |
| Smoking: unknown | 1.000 | 1.000 | 1.000 | 1.000 | 1.000 |
| Smoking: past | 0.85 | 0.52 | 1.37 | 0.498 | 0.619 |
| Smoking: current | 1.60 | 1.05 | 2.44 | 0.028 | 0.012 |
| Smoking: never | 0.98 | 0.96 | 1.00 | 0.97 | 0.677 |
| Age | 1.60 | 1.05 | 2.44 | 0.028 | 0.012 |
| History of exacerbations | 1.72 | 1.54 | 1.91 | <0.001 | 0.010 |
| Allergic rhinitis | 0.98 | 0.64 | 1.51 | 0.931 | 0.079 |
| Sinusitis | 0.77 | 0.32 | 1.92 | 0.587 | 0.001 |
| Depression | 1.53 | 0.87 | 2.68 | 0.142 | 0.016 |
| Lower respiratory tract infection | 0.66 | 0.40 | 1.09 | 0.103 | 0.001 |
| Smoking: never | ref | ref | ref | ref | ref |
| Smoking: current | 0.72 | 0.44 | 1.17 | 0.183 | 0.010 |
| Smoking: past | 0.43 | 0.19 | 0.98 | 0.044 | 0.001 |
| Smoking: unknown | 0.85 | 0.52 | 1.37 | 0.498 | 0.619 |

* GERD = Gastro-oesophageal reflux disease.

### Table 3

Full model to estimate the relative risk of severe asthma exacerbations in all patients and in mixed patients (patients who had exposure to LAMA mono as well as exposure to LAMA + ICS, but never triple therapy (LAMA + ICS + LABA).

| Treatment exposure periods (n = 3596) considering all patients (n = 1236) | Treatment exposure periods (n = 329) considering mixed patients (n = 74) only |
|-------------------------------------------------|-------------------------------------------------|
| Relative Risk | 95% CI | p-value | Relative Risk | 95% CI | p-value |
| Mono therapy | 1.50 | 0.60 | 3.80 | 0.387 | 0.016 |
| Dual therapy | 2.75 | 1.13 | 6.68 | 0.025 | 0.012 |
| Triple therapy | 1.60 | 1.05 | 2.44 | 0.028 | 0.012 |
| Female sex | 0.98 | 0.96 | 1.00 | 0.97 | 0.677 |
| Age | 1.72 | 1.54 | 1.91 | <0.001 | 0.010 |
| History of exacerbations | 0.98 | 0.64 | 1.51 | 0.931 | 0.079 |
| Allergic rhinitis | 0.77 | 0.32 | 1.92 | 0.587 | 0.001 |
| Sinusitis | 1.53 | 0.87 | 2.68 | 0.142 | 0.016 |
| Depression | 0.66 | 0.40 | 1.09 | 0.103 | 0.001 |
| Smoking: never | ref | ref | ref | ref | ref |
| Smoking: current | 0.72 | 0.44 | 1.17 | 0.183 | 0.010 |
| Smoking: past | 0.43 | 0.19 | 0.98 | 0.044 | 0.001 |
| Smoking: unknown | 0.85 | 0.52 | 1.37 | 0.498 | 0.619 |

4. Discussion

In this cohort study, we describe real-life prescription patterns of LAMA therapy in asthmatic patients. In this Dutch cohort, less than 2% of asthmatic patients were prescribed LAMA therapy. However, in almost 4 out of 10 LAMA prescriptions a co-prescription of ICS was lacking in the database. Yet 14% of patients prescribed LAMA therapy already experienced severe asthma exacerbations in the year prior. This again confirms that these patients had an indication to receive inhaled corticosteroids. We observed a predominance in female gender in our study population, which is in line with the occurrence of asthma in adulthood [13]. Importantly, in this study we have shown that patients using LAMA monotherapy have an increased risk of severe asthma exacerbations compared to using LAMA with an ICS. This was observed in patients with and without a history of severe asthma exacerbations.

Interpretation of the risk of asthma exacerbations is complex. We know from literature that the a-priori risk of exacerbations depends on the severity of asthma, as well as the adherence to medication and life style changes such as smoking. Asthma treatment step-up is driven by
have cautioned not to use reliever therapy without a concomitant monotherapy and several studies showing the danger of SABA overuse that a prescription of ICS definitely was indicated. A patient with a history of a severe asthma exacerbation confirms observational cohort study provides important insight in real-life asthma management. The strengths of this study is multiple. First, we had access to a large cohort of asthmatic patients, being able to capture sufficient LAMA prescriptions even though the prevalence of LAMA use in asthma patients is low. Secondly, in the Netherlands every inhabitant is registered with a general practitioner (GP) who acts as a gatekeeper to specialist health care and all data is registered as part of usual care. Therefore, the risk of information bias is minimal. Thirdly, all exacerbations were manually validated by reviewing the patient’s file (free text validation) to minimize misclassification of the outcome. Lastly, in the Netherlands, the drugs mentioned in the study are included in all standard health insurance packages. Therefore, the choice of drug does not depend on differences in health insurance.

However, as with all observational studies there are limitations inherent to the study design. Indeed, data on asthma control such as asthma control questionnaires or lung function tests were not routinely collected. Since the study was conducted in a primary care database, prescriptions by specialists might be missed. Importantly, misclassification of asthma diagnosis was possible since asthma diagnosis was based on asthma diagnostic codes in combination with use of respiratory drugs. However, to reduce the potential of misclassification between asthma and COPD – which could be a concern as LAMA monotherapy is indicated for the treatment of COPD (GOLD stage II), we excluded patients with both a disease code of asthma and COPD and limited the population to individuals younger than 50 years. Moreover, stratified analyses according to smoking status showed that the risk of SAE in non-smokers (where the risk of misclassification of COPD is rare) was still significantly increased for patients using LAMA monotherapy (see online supplements). This is an important clinical message for patients and physicians.

What is the clinical relevance of our finding? In this cohort study, we found that – although use of LAMA in asthma is low - many patients are prescribed a LAMA without concomitant ICS, despite that this is clearly discouraged in national and international asthma guidelines. Moreover, although the absolute risks remain low, we found an increased risk of exacerbations during periods of LAMA monotherapy in patients alternating between mono and dual therapy. This was found in both patients with a history of severe asthma exacerbations and without a history of severe asthma exacerbations. These findings emphasize that monitoring of ICS use when prescribing LAMA should be a key strategy to improve asthma care. Developing fixed combinations of LAMA and ICS, or using triple inhaled therapy (LAMA + LABA + ICS) might prevent the use of LAMA as monotherapy in patients with asthma.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

CRediT authorship contribution statement

E.J. Baan: Conceptualization, Methodology, Validation, Formal analysis, Writing – review & editing. C.E. Hoeve: Conceptualization, Methodology, Validation, Formal analysis, Writing – review & editing. M. De Ridder: Conceptualization, Methodology, Writing – review & editing. L. Deneen: Validation, Investigation. L. Lahousse: Writing – review & editing. G.G. Brusselle: Supervision, Writing – review & editing. K.M.C. Verhamme: Conceptualization, Supervision, Writing – review & editing.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.pupt.2021.102074.
References

[1] Global initiative for Asthma, GINA Report, Global Strategy for Asthma Management and Prevention. 2019, 2019. Available from: http://ginasthma.org/gina-reports/.

[2] Tiotropium - what role in asthma? Drug Therapeut. Bull. 53 (9) (2015) 102–104.

[3] D.M. Sobieraj, et al., Association of inhaled corticosteroids and long-acting muscarinic antagonists with asthma control in patients with uncontrolled, persistent asthma: a systematic review and meta-analysis, J. Am. Med. Assoc. 319 (14) (2018) 1473–1484.

[4] C. Vogelberg, et al., A comparison of tiotropium, long-acting beta2-agonists and leukotriene receptor antagonists on lung function and exacerbations in paediatric patients with asthma, Respir. Res. 21 (1) (2020) 19.

[5] A.C. Wu, et al., Primary adherence to controller medications for asthma is poor, Ann Am Thorac Soc 12 (2) (2015) 161–166.

[6] C.M. Averell, et al., Characterizing real-world use of tiotropium in asthma in the USA, J. Asthma Allergy 12 (2019) 309–321.

[7] H.S. Nelson, et al., The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol, Chest 129 (1) (2006) 15–26.

[8] B.I. Nwaru, et al., Overuse of Short-Acting Beta2-Agonists in Asthma Is Associated with Increased Risk of Exacerbation and Mortality: A Nationwide Cohort Study of the Global SABINA Programme, Eur Respir J, 2020.

[9] A.E. Vlug, J. van der Lei, B. Mouwveld, Postmarketing surveillance based on electronic patient records: the IPCI project, Method Inf. Med. 38 (4) (1999) 339–344.

[10] H.K. Reddel, et al., An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice, Am. J. Respir. Crit. Care Med. 180 (1) (2009) 59–99.

[11] E.R. Bousie, et al., ERS/EAACI statement on severe exacerbations in asthma in adults: facts, priorities and key research questions, Eur. Respir. J. 54 (3) (2019).

[12] NHG-werkgroep, J.W. Botema, M. Bouma, L. Broekhuizen, N.H. Chavannes, L.A. M. Frankemolle, C. Hallensleben, J. De Jong, J.W.M. Muris, S.A. Van Nederven-Bendien, S.F. Van Vugt, NHG-standaard Astma Bij Volwassenen (M27), 2020. www.nhg.org.

[13] J.W. McCallister, J.G. Mastronarde, Sex differences in asthma, J. Asthma 45 (10) (2008) 853–861.

[14] D. Price, et al., Predicting frequent asthma exacerbations using blood eosinophil count and other patient data routinely available in clinical practice, J. Asthma Allergy 9 (2016) 1–12.

[15] S. Al-ani, et al., Predictors of exacerbations of asthma and COPD during one year in primary care, Fam. Pract. 30 (6) (2013) 621–628.

[16] D. Price, et al., Long-acting muscarinic antagonist use in adults with asthma: real-life prescribing and outcomes of add-on therapy with tiotropium bromide, J. Asthma Allergy 8 (2015) 1–13.

[17] W.C. Cheng, et al., Clinical predictors of the effectiveness of tiotropium in adults with symptomatic asthma: a real-life study, J. Thorac. Dis. 10 (6) (2018) 3661–3669.

[18] Nederlandse Vereniging van Artsen voor Longziekten en Tuberculose (NVALT) Richtlijn diagnostiek en behandeling van ernstig astma, 2013. Available from: https://www.nvalt.nl/kwaliteit/richtlijnen/copd-astma-allergie last date. Accessed 4 February 2020.

[19] B.M. Sneeke I, B.D.L. Broekhuizen, N.H. Chavannes, J.C.C.M. ’t Veen, T. Van der Molen, J.W. Muris, O. Van Schayck, T.R.J. Schermer, J.B. Sneeck-Stroband, R.M. M. Geijer, M.K. Tuut, NHG-Werkgroep Astma bij volwassenen en COPD, NHG-Standaard Astma bij volwassenen (Dere herziening), 2015. Available from, www.nhg.org. (Accessed 24 February 2020).

[20] U.S. Food and Drug Administration, FDA Drug Safety Communication: drug labels now contain updated recommendations on the appropriate use of long-acting inhaled asthma medications called Long-Acting Beta-Agonists (LABAs), Last date accessed 06/02/2020, 2010, http://wayback.archive-it.org/7993/20170112031853/http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm213836.htm.

[21] R. Normansell, K.M. Kew, E. Stovold, Interventions to improve adherence to inhaled steroids for asthma, Cochrane Database Syst. Rev. 4 (2017) CD012226.

[22] H.H. De Keyser, R. Ramsey, M.J. Federico, They Just Don’t Take Their Medicines: Reframing Medication Adherence in Asthma from Frustration to Opportunity, Pediatr Pulmonol, 2020.